IMAC (BACK) Competitors $0.05 -0.01 (-19.35%) As of 07/3/2025 11:31 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock BACK vs. BTTX, UPHL, ACONW, AONC, DHACW, FMS, LFMDP, OTRKP, PIIIW, and TALKWShould you be buying IMAC stock or one of its competitors? The main competitors of IMAC include Better Therapeutics (BTTX), UpHealth (UPHL), Aclarion (ACONW), American Oncology Network (AONC), Digital Health Acquisition (DHACW), Fresenius Medical Care AG & Co. KGaA (FMS), LifeMD (LFMDP), Ontrak (OTRKP), P3 Health Partners (PIIIW), and Talkspace (TALKW). These companies are all part of the "healthcare" industry. IMAC vs. Its Competitors Better Therapeutics UpHealth Aclarion American Oncology Network Digital Health Acquisition Fresenius Medical Care AG & Co. KGaA LifeMD Ontrak P3 Health Partners Talkspace Better Therapeutics (NASDAQ:BTTX) and IMAC (NASDAQ:BACK) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment. Do insiders and institutionals believe in BTTX or BACK? 34.0% of Better Therapeutics shares are owned by institutional investors. Comparatively, 5.8% of IMAC shares are owned by institutional investors. 51.4% of Better Therapeutics shares are owned by insiders. Comparatively, 12.3% of IMAC shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility & risk, BTTX or BACK? Better Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, IMAC has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500. Is BTTX or BACK more profitable? Company Net Margins Return on Equity Return on Assets Better TherapeuticsN/A N/A N/A IMAC N/A N/A -325.44% Does the media favor BTTX or BACK? In the previous week, IMAC had 11 more articles in the media than Better Therapeutics. MarketBeat recorded 11 mentions for IMAC and 0 mentions for Better Therapeutics. IMAC's average media sentiment score of 0.27 beat Better Therapeutics' score of 0.00 indicating that IMAC is being referred to more favorably in the news media. Company Overall Sentiment Better Therapeutics Neutral IMAC Neutral Which has higher valuation & earnings, BTTX or BACK? IMAC has higher revenue and earnings than Better Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBetter TherapeuticsN/AN/A-$39.76MN/AN/AIMAC$72.05K1.44-$9.42MN/AN/A SummaryIMAC beats Better Therapeutics on 5 of the 8 factors compared between the two stocks. Get IMAC News Delivered to You Automatically Sign up to receive the latest news and ratings for BACK and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BACK vs. The Competition Export to ExcelMetricIMACSpecialty outpatient clinics IndustryMedical SectorNASDAQ ExchangeMarket Cap$104K$104K$5.56B$9.04BDividend YieldN/AN/A5.24%4.01%P/E RatioN/AN/A27.6420.24Price / Sales1.441.44416.55117.31Price / CashN/AN/A36.8958.10Price / Book-0.08N/A8.035.67Net Income-$9.42M-$9.42M$3.18B$249.21M7 Day PerformanceN/AN/A2.93%3.28%1 Month PerformanceN/AN/A1.72%3.95%1 Year PerformanceN/AN/A34.39%20.98% IMAC Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BACKIMACN/A$0.05-19.4%N/A-97.2%$104K$72.05K0.00180Gap DownBTTXBetter TherapeuticsN/A$0.00flatN/AN/A$5KN/A0.0040High Trading VolumeUPHLUpHealthN/A$0.00flatN/A-100.0%$4K$130M0.001,750ACONWAclarionN/A$0.04+16.8%N/A-10.9%$0.00$54.60K0.007AONCAmerican Oncology NetworkN/A$12.87-7.3%N/A+932.7%$0.00$1.34B0.001,520DHACWDigital Health AcquisitionN/A$0.04flatN/A-82.2%$0.00N/A0.00N/AFMSFresenius Medical Care AG & Co. KGaA2.994 of 5 stars$27.75+2.2%$27.80+0.2%+43.0%$0.00$20.63B24.771,384Analyst UpgradeLFMDPLifeMDN/A$23.79-1.1%N/A+5.6%$0.00$234.01M0.00230OTRKPOntrakN/A$0.23-1.6%N/A-7.6%$0.00$10.84M0.00250News CoverageGap DownPIIIWP3 Health PartnersN/A$0.01-19.1%N/A-86.6%$0.00$1.49B0.00500Positive NewsGap UpTALKWTalkspaceN/A$0.07-0.3%N/A+13.3%$0.00$194.36M0.00500 Related Companies and Tools Related Companies Better Therapeutics Competitors UpHealth Competitors Aclarion Competitors American Oncology Network Competitors Digital Health Acquisition Competitors Fresenius Medical Care AG & Co. KGaA Competitors LifeMD Competitors Ontrak Competitors P3 Health Partners Competitors Talkspace Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BACK) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.The robotics revolution is here. And it's set to impact everything from how we manufacture goods to how we ...Weiss Ratings | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IMAC Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IMAC With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BACK Stock Alerts